Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Undisclosed Program 2 (Atalanta Therapeutics)
- Development stage
- Preclinical
- Lead developer
- Atalanta Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Undisclosed Program 2 is a discovery-stage therapeutic program being developed by Atalanta Therapeutics for the treatment of central nervous system (CNS) disorders. The program utilizes Atalanta's proprietary branched siRNA (di si-RNA) technology, which features a unique dicer-substrate siRNA architecture designed for enhanced stability and distribution. This platform is engineered to achieve widespread gene silencing throughout the brain and spinal cord, addressing the delivery challenges typically associated with RNA interference in the CNS. While the specific molecular targets remain undisclosed, the program aims to leverage the RNAi pathway to downregulate the expression of multiple disease-causing genes involved in CNS pathology.
- Other names
- Atalanta CNS Program 2Atalanta Therapeutics-Multiple targets (undisclosed)-siRNA (dicer-substrate / di si-RNA)-CNS Disorders
Beyond the preview
Go deeper on Undisclosed Program 2 (Atalanta Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Undisclosed Program 2 (Atalanta Therapeutics).